{"id":"3b2ad9ad-08fa-59b5-a9a6-d5e4b64dad89","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-erp57-assay","predicate":"decreases_in_recorded_comparison","statement":"RA inhibited recombinant ERp57-dependent insulin reduction, IC50 176.82 micromolar.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"8deef675-f606-5d5d-8d3e-f503549774ff","mechanism_event_label":"RA inhibited recombinant ERp57-dependent insulin reduction, IC50 176.82 micromolar.","subject":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"object":{"id":"b60fc2ab-217e-503c-9bb5-39e655ee618e","slug":"ra-erp57-recombinant-preparation","display_name":"Recombinant ERp57 preparation in the 2018 RA study","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"8deef675-f606-5d5d-8d3e-f503549774ff","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-erp57-assay-event","event_type":"experimental_observation","label":"RA inhibited recombinant ERp57-dependent insulin reduction, IC50 176.82 micromolar.","description":"### ra-erp57-assay\n\nRA inhibited recombinant ERp57-dependent insulin reduction, IC50 176.82 micromolar.\nDocking contacts are predictions. Enzyme inhibition plus platelet inhibition does not alone prove ERp57 mediates the platelet effect.\nModel and exposure: 2018 DTT-containing turbidity assay, 84 min; recombinant construct species not stated explicitly in Methods.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Discovery of a Novel ERp57 Inhibitor as Antiplatelet Agent from Danshen <i>(Salvia miltiorrhiza)</i>. | 2018 | https://pubmed.ncbi.nlm.nih.gov/29849736/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5941821/ | https://doi.org/10.1155/2018/9387568 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"RA concentration series","sequence_order":0,"notes":""},{"entity":{"id":"b60fc2ab-217e-503c-9bb5-39e655ee618e","slug":"ra-erp57-recombinant-preparation","display_name":"Recombinant ERp57 preparation in the 2018 RA study","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"RA concentration series\", \"comparator\": \"Vehicle\", \"endpoint\": \"RA inhibited recombinant ERp57-dependent insulin reduction, IC50 176.82 micromolar.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"2018 DTT-containing turbidity assay, 84 min; recombinant construct species not stated explicitly in Methods.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"RA inhibited recombinant ERp57-dependent insulin reduction, IC50 176.82 micromolar.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Discovery of a Novel ERp57 Inhibitor as Antiplatelet Agent from Danshen <i>(Salvia miltiorrhiza)</i>. | https://pubmed.ncbi.nlm.nih.gov/29849736/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5941821/ | https://doi.org/10.1155/2018/9387568","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-erp57-assay; Docking contacts are predictions. Enzyme inhibition plus platelet inhibition does not alone prove ERp57 mediates the platelet effect.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"404df995-cc93-52b1-8be3-39454025ed38","evidence_kind":"source_excerpt","locator":"Lines 562-568","start_line":562,"end_line":568,"excerpt":"### ra-erp57-assay\n\nRA inhibited recombinant ERp57-dependent insulin reduction, IC50 176.82 micromolar.\nDocking contacts are predictions. Enzyme inhibition plus platelet inhibition does not alone prove ERp57 mediates the platelet effect.\nModel and exposure: 2018 DTT-containing turbidity assay, 84 min; recombinant construct species not stated explicitly in Methods.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Discovery of a Novel ERp57 Inhibitor as Antiplatelet Agent from Danshen <i>(Salvia miltiorrhiza)</i>. | 2018 | https://pubmed.ncbi.nlm.nih.gov/29849736/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5941821/ | https://doi.org/10.1155/2018/9387568 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"2018 DTT-containing turbidity assay, 84 min; recombinant construct species not stated explicitly in Methods.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}